In March 2021, the healthcare industry reported 119 deals worth $10.8 billion as compared to the last 12-month average (March 2020 to February 2021) of 94 deals worth $20 billion.

Amgen Inc, a biopharmaceutical company, to acquire Five Prime Therapeutics Inc, a clinical-stage biotechnology company for $38 per share in cash, representing an equity value of approximately $1,900 million; Altaris Capital Partners, LLC, a private equity firm, to acquire Generic Rx Pharmaceuticals business of Perrigo Company plc for $1,550 million in cash; and Abu Dhabi Developmental Holding Company PJSC to acquire Amoun Pharmaceutical Company S.A.E., a company engaged in the development, manufacturing, marketing, distribution, and export of human pharmaceutical and animal health products for $740 million are the three major deals reported in March 2021.

Venture Capital Investments Increased by 45.9 per cent in March 2021, compared to February 2021

The healthcare industry reported 187 venture capital (VC) deals worth $8.1billion in March 2021, compared to the last 12-month average (March 2020 to February 2021) of 140 deals worth $4 billion.

ElevateBio LLC, raising $525 million in series C round of financing to expand and advance its technology to accelerate the production and development of life-saving cell and gene therapies; Insitro Inc, raising $400 million in series C  round of financing to reshape drug discovery and development of transformative medicine; and AffaMed Therapeutics Shanghai Ltd, raising $170 million in series B round of financing to further develop its Ophthalmic and Neuroscience pipeline are the major VC deals reported in March 2021.